Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Novacyt   /   Novacyt de volgende biotech raket!

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

Laatste koers (eur) Verschil Volume
0,630   -0,006   (-0,94%) Dagrange 0,626 - 0,645 149.116   Gem. (3M) 1,2M

Novacyt de volgende biotech raket!

Volgen
70.761 Posts
Pagina: «« 1 ... 3217 3218 3219 3220 3221 ... 3539 »» | Laatste | Omlaag ↓
  7. forum rang 10 DeZwarteRidder 16 september 2021 08:49
    quote:

    Ronster schreef op 16 september 2021 08:47:

    novacyt.com/wp-content/uploads/2021/0...

    Persbericht van deze ochtend.
    Proposed accounting treatment of ongoing DHSC
    dispute in 2021 interim results

    Paris, France and Camberley, UK – 16 September 2021 – Novacyt (EURONEXT
    GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,
    announces the proposed accounting treatment of the ongoing DHSC dispute on its
    unaudited H1 2021 interim results for the six months ended 30 June 2021. The interim
    results are expected to be announced on 27 September 2021.

    There has been no further update to the announcement made at the time of the Company’s
    full year results on 22 June 2021, and subsequent half year update on 18 August 2021, in
    relation to the DHSC dispute. The accounting treatment of the DHSC revenue and costs in
    H1 2021, detailed below, does not change the Company’s legal position or rights in relation
    to the dispute. The Company continues to work with its legal advisers to progress the
    dispute and believes it has strong grounds to assert its contractual rights.

    The Company reiterates revenue guidance, excluding the disputed DHSC revenue, for the
    full year of approximately £100 million and underlying EBITDA margin of approximately
    40%, as announced on 22 June 2021. However, the full year Group EBITDA margin could
    be materially affected by the outcome of the ongoing dispute with the DHSC and the write
    down of inventory as detailed below.

    At the time of the Company’s half year update on 18 August 2021, it was noted that £40.8
    million of revenue in H1 2021 was in dispute with the DHSC. For the purposes of the
    interim results, the Company is required to apply the applicable accounting standards to
    the disputed revenues. The Board has therefore taken a conservative approach and
    decided that while the dispute with the DHSC remains unresolved the Company will not
    recognise the H1 2021 revenue of £40.8 million from the DHSC, in line with IFRS 15
    accounting standard on revenue from contracts with customers. The remaining H1 2021
    revenue of £54.0 million from non-DHSC sales remains unchanged.

    In addition to not recognising the £40.8 million of DHSC sales in its interim results, the
    Company has prudently decided to recognise manufacturing costs of £6.9 million relating
    to these disputed sales.

    The Company is also taking an exceptional one-off cost of £28.9m to write down inventory
    that the Company had built in anticipation of further DHSC demand and to terminate
    supply commitments with third parties in respect of this supply that are no longer required.
    This inventory build was Novacyt’s direct response to support the UK Government’s call
    for UK manufacturers to build manufacturing capacity and supply chain flexibility in
    response to the COVID-19 pandemic and was based on likely demand indicated by DHSC.
    The Company will continue to look for ways to use this inventory.

    As announced on 18 August 2021, Novacyt continues to supply PROmate® COVID-19 tests
    to the NHS under the terms of a new contract awarded by the DHSC under the Public
    Health England National Microbiology Framework.

    £'000 H1 2021
    Underlying
    H1 2021
    DHSC
    dispute
    impact
    H1 2021
    Total Group

    Total Group Revenue 53,950 53,950

    Gross Profit 38,044 (35,770) 2,274
    GP % 71% 4%

    EBITDA
    EBITDA %

    23,169
    43%

    (35,770)

    (12,601) -23%

    Consistent with the announcement on 22 June 2021, the underlying business will generate
    gross profit of approximately 71% of sales and EBITDA of approximately 43% of sales for
    the half year, excluding the impact of the DHSC dispute. The Company’s cash position as
    at 30 June 2021 was £77.2 million.

    This announcement contains inside information for the purposes of Article 7 of Regulation
  13. forum rang 10 voda 16 september 2021 09:11
    Ik was er al bang voor toen ik het PB las. De zweer die DHSC heet, kan nog steeds niet genezen.
    De beleggers nemen helaas weer afscheid van het aandeel. Het wachten duurt inmiddels wel erg lang.

    Het geduld wordt wel enorm op de proef gesteld zeg. Houd de aandelen gewoon vast, verkopen is geen optie (meer).
  19. [verwijderd] 16 september 2021 09:20
    quote:

    Sun120 schreef op 16 september 2021 09:17:

    Dit nieuws was al bekend dus ??? Ze hebben nieuwe contracten en testen zal terug meer gaan gebeuren daar ben ik zeker van overtuigd. En ik zou er niet van verschieten dat hier sevens weeral berichten zullen verschijnen van zie je wel ik had jullie gewaarschuwd :-)
    DE MONITOR - Dé Pharming Expert was daar gisteren avond al mee bezig , nee , met Pharming gaat het goed :-)
    Oh ja , Trab , die missen we nog maar zal niet lang duren :-)
70.761 Posts
Pagina: «« 1 ... 3217 3218 3219 3220 3221 ... 3539 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee